CERTOLIZUMAB PEGOL IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS

CERTOLIZUMAB PEGOL IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS

The paper gives the results of the RAPID-axSpA study that has evaluated for the first time the efficacy of the tumor necrosis factor-α (TNF-α) inhibitor certolizumab pegol (CZP) in treatment of axial spondyloarthritis (axSpA) clinical forms: already developed ankylosing spondylitis and non-radiograp...

Full description

Bibliographic Details
Main Author: Sh. F. Erdes
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2016-02-01
Series:Научно-практическая ревматология
Subjects:
axial spondyloarthritis
ankylosing spondylitis
sacroiliitis
tumor necrosis factor-α inhibitors
certolizumab pegol.
Online Access:https://rsp.mediar-press.net/rsp/article/view/2156

Internet

https://rsp.mediar-press.net/rsp/article/view/2156

Similar Items